KR102575452B1 - Microorganism strain having activity of improving liver function and use thereof - Google Patents

Abstract

The present invention relates to strains having liver function improving activity and uses thereof, and specifically, the present invention relates to Lactobacillus pentosus KF8 (Accession No. KCCM11997P) strain, Bacillus subtilis KF11 (Accession No. KCCM11981P) strain and Lactococcus lac This relates to a health food composition for improving liver function and a pharmaceutical composition for improving liver function, comprising at least one strain selected from the group consisting of strains KF140 (accession number KCCM11673P), a lysate thereof, or a culture thereof as an active ingredient. The strain of the present invention inhibits ALT (Alanine Aminotransferase) or AST (Aspartate Aminotransferase) activity, suppresses the increase in the concentration of total cholesterol or triglyceride in the liver, and has excellent activity to inhibit fat accumulation in the liver, thereby improving liver function It can be usefully used for the preparation of food compositions and pharmaceutical compositions for.

Description

Microorganism strain having activity of improving liver function and use thereof {Microorganism strain having activity of improving liver function and use thereof}

The present invention is a strain having liver function improving activity and a use thereof, and specifically, the present invention relates to Lactobacillus pentosus KF8 (Accession No. KCCM11997P) strain, Bacillus subtilis KF11 (Accession No. KCCM11981P) strain or Lactococcus lactis KF140. (Accession No. KCCM11673P) It relates to a health food composition and pharmaceutical composition for improving liver function using a strain.

It is known that the liver is closely related to mental activity, performing blood storage and circulation, blood volume control and defense detoxification in the human body. Our bodies are always exposed to pollutants and toxic substances due to industrialization, so our liver is constantly suffering from detoxification.

In addition, the liver is an organ with a large buffering capacity, so it does not appear well in the early stages of the disease and is only discovered when it is significantly deteriorated. Liver cirrhosis, liver cancer, etc. are common last stages of chronic liver disease. Causes include alcohol, drugs, chemicals, viral hepatitis, biliary tract disease, metabolic diseases such as hemochromatosis, and autoimmune diseases. It is an institution.

Recently, the mortality rate due to liver cancer in terms of health of Koreans is 23.4 per 100,000 people, ranking first in the world, and the case of chronic liver disease is also ranked third at 28.8. In addition, the National Statistical Office recently announced that 56.1 deaths per 100,000 people in Korea in their 40s are the highest cause of death due to liver disease, and liver disease is emerging as an important social problem. Research on improving liver function is becoming more focused.

On the other hand, probiotics have been used in our diet for a long time, and in particular, beneficial effects such as intestinal function, anticancer effect, and immune enhancing effect have been reported.

Accordingly, the present inventors have developed probiotics, in particular, Lactobacillus pentosus KF8 (accession number KCCM11997P) strain, Bacillus subtilis KF11 (accession number KCCM11981P) strain, and Lactococcus, which are strains isolated and identified as new strains by the present inventors through previous studies. The present invention was completed by confirming that the bacteria can effectively improve liver function while studying the new physiological activity of the lactis KF140 (accession number KCCM11673P) strain.

Republic of Korea Patent Publication No. 10-2018-0103772

Therefore, an object of the present invention is at least one selected from the group consisting of Lactobacillus pentosus KF8 (Accession No. KCCM11997P) strain, Bacillus subtilis KF11 (Accession No. KCCM11981P) strain and Lactococcus lactis KF140 (Accession No. KCCM11673P) strain. It is to provide a health food composition for improving liver function comprising a strain, its lysate or its culture as an active ingredient.

Another object of the present invention is one selected from the group consisting of Lactobacillus pentosus KF8 (Accession No. KCCM11997P) strain, Bacillus subtilis KF11 (Accession No. KCCM11981P) strain and Lactococcus lactis KF140 (Accession No. KCCM11673P) strain. It is to provide a pharmaceutical composition for improving liver function comprising the above strain, its lysate or its culture as an active ingredient.

In order to achieve the object of the present invention as described above, the present invention is Lactobacillus pentosus KF8 (Accession No. KCCM11997P) strain, Bacillus subtilis KF11 (Accession No. KCCM11981P) strain and Lactococcus lactis KF140 (Accession No. KCCM11673P) It provides a health food composition for improving liver function, comprising at least one strain selected from the group consisting of strains, a lysate thereof, or a culture thereof as an active ingredient.

In one embodiment of the present invention, the composition inhibits ALT (Alanine Aminotransferase) or AST (Aspartate Aminotransferase) activity, inhibits an increase in total cholesterol or triglyceride concentration in the liver, or inhibits fat accumulation in the liver. can

In one embodiment of the present invention, the health food composition may be any one formulation selected from powder, granule, pill, tablet, capsule, candy, syrup and beverage.

In addition, the present invention is one or more strains selected from the group consisting of Lactobacillus pentosus KF8 (Accession No. KCCM11997P) strain, Bacillus subtilis KF11 (Accession No. KCCM11981P) strain and Lactococcus lactis KF140 (Accession No. KCCM11673P) strain, It provides a pharmaceutical composition for improving liver function, containing its lysate or its culture as an active ingredient.

In one embodiment of the present invention, the composition inhibits ALT (Alanine Aminotransferase) or AST (Aspartate Aminotransferase) activity, inhibits an increase in total cholesterol or triglyceride concentration in the liver, or inhibits fat accumulation in the liver can do.

The present invention relates to one or more strains selected from the group consisting of Lactobacillus pentosus KF8 (Accession No. KCCM11997P) strain, Bacillus subtilis KF11 (Accession No. KCCM11981P) strain and Lactococcus lactis KF140 (Accession No. KCCM11673P) strain, It relates to a health food composition for improving liver function and a pharmaceutical composition for improving liver function comprising a lysate or its culture as an active ingredient, wherein the strain of the present invention inhibits ALT (Alanine Aminotransferase) or AST (Aspartate Aminotransferase) activity It has an excellent activity to inhibit the increase in total cholesterol or triglyceride concentration in the liver and the accumulation of fat in the liver, so it can be usefully used in the preparation of food compositions and pharmaceutical compositions for improving liver function.

1 is prepared using Lactobacillus pentosus KF8 (Accession No. KCCM11997P) strain, Bacillus subtilis KF11 (Accession No. KCCM11981P) strain and Lactococcus lactis KF140 (Accession No. KCCM11673P) strain in one embodiment of the present invention. This is a picture showing the form of health food for improving liver function.

The present invention relates to a novel use of a strain having liver function improving activity, wherein the strain having liver function improving activity is Lactobacillus pentosus KF8 (Accession No. KCCM11997P) previously isolated and identified and published by the inventor of the present invention for the first time. The strains, Bacillus subtilis KF11 (accession number KCCM11981P) strain and Lactococcus lactis KF140 (accession number KCCM11673P) strain.

The present inventors performed an experiment to confirm whether the strain of the present invention can improve liver function and has liver-protecting activity. As a result, the food form prepared by powdering the strain was used as a liver damage animal model. As a result of administration, it was confirmed that the effect of protecting liver cells and inhibiting ALT and AST activities, which are indicators of liver damage, was excellent.

ALT (Aspartate Aminotransferase) is a typical indicator of liver damage. It is an enzyme found in the liver, kidneys, heart, muscle, etc., and is present in the largest amount in the liver. It reacts sensitively to liver cell damage and increases its level, so it is used as an indicator of liver disease. . Mainly when the liver is damaged for various reasons, it is released into the blood and blood levels rise.

In addition, since AST (alanine aminotransferase), another indicator of liver damage, is also released into the blood during liver damage and the blood level rises compared to the normal state, the degree of liver damage can be confirmed by measuring the content of these indicators.

On the other hand, the strains of the present invention, Lactobacillus pentosus KF8 (Accession No. KCCM11997P) strain, Bacillus subtilis KF11 (Accession No. KCCM11981P) strain or Lactococcus lactis KF140 (Accession No. KCCM11673P) strain were administered to mice with liver damage. As a result of administration to the group, it was confirmed that there was an effect of reducing the increased ALT and AST levels in the blood by more than two times.

In addition, in one embodiment of the present invention, it was analyzed whether the increased content of total cholesterol and triglyceride in the liver due to the onset of fatty liver could be reduced when the strain of the present invention was administered. The result of administering the strain of the present invention to a fatty liver animal model , it was confirmed that the contents of total cholesterol and triglyceride in the liver were effectively suppressed, and it was confirmed that the accumulation of fat in the liver was suppressed.

Fatty liver is known to be caused by inhibition of lipoprotein formation and release in the liver or enhancement of triglyceride synthesis. Ethionine inhibits the synthesis of RNA and protein, thereby reducing the production of ATP in the liver, thereby inhibiting the release of neutral fat into the plasma, and also inhibiting the synthesis of lipoproteins, resulting in secondary depletion of lipids from the liver. Since it suppresses the release of ethionine, when ethionine is administered, triglyceride in the liver tissue accumulates, and the amount of triglyceride and total cholesterol in the blood decreases rapidly, causing microvasicular steatosis. Therefore, in the fatty liver model induced by ethionine, the triglyceride content in liver tissue and the total cholesterol content in serum are used as model indicators.

In this regard, it can be seen that the strain of the present invention is useful for improving and treating fatty liver because it was confirmed that there is an effect of reducing triglyceride and total cholesterol in liver tissue.

Furthermore, in another embodiment of the present invention, as a result of conducting a clinical trial on volunteers conducted according to the regulations of the Institutional Review Board (IRB), the group who consumed the health food prepared using the strain of the present invention case, it was found that the activity of ALT and AST in the blood was suppressed compared to the group that did not consume it, and it was found that there was an effect of improving liver function, and it was confirmed that the content of total cholesterol and LDL cholesterol was also reduced by ingestion of the strain of the present invention. could

Therefore, through these results, the present inventors found that the strains first isolated and identified by the present inventors, Lactobacillus pentosus KF8 (accession number KCCM11997P) strain, Bacillus subtilis KF11 (accession number KCCM11981P) strain, or Lactococcus lactis KF140 It was found that the strain (accession number KCCM11673P) could be used for improving liver function.

Therefore, the present invention provides one or more strains selected from the group consisting of Lactobacillus pentosus KF8 (Accession No. KCCM11997P) strain, Bacillus subtilis KF11 (Accession No. KCCM11981P) strain and Lactococcus lactis KF140 (Accession No. KCCM11673P) strain, It is possible to provide a health food composition for improving liver function, including its lysate or its culture as an active ingredient.

The number of strains that may be contained in the health food composition for improving liver function of the present invention may be 1.0×10 ⁵ CFU/g to 2.0×10 ¹⁵ CFU/g, and the health food composition of the present invention includes among the strains. , It may include one type of strain, or may include one or more types of mixed strains, and most preferably may include a mixed strain in which all three types of strains are mixed.

Liver function improvement effect of the Lactobacillus pentosus KF8 (Accession No. KCCM11997P) strain, Bacillus subtilis KF11 (Accession No. KCCM11981P) strain or Lactococcus lactis KF140 (Accession No. KCCM11673P) strain identified in the experiments of the present invention, That is, inhibition of ALT and AST activity in blood, inhibition of total cholesterol and triglyceride in liver tissue, and inhibition of fat accumulation in liver can be induced even by the treatment of the single strain, and when two or more strains are mixed, a better effect is obtained. It can be shown, and the best effect can be shown when all three strains are mixed. In the present invention, the food composition includes all forms such as functional food, nutritional supplement, health food, and food additives. Food compositions of this type can be prepared in various forms according to conventional methods known in the art. For example, as a health food, the strain strain itself, its lysate, and at least one of the strain culture groups of the present invention are prepared in the form of tea, juice, and drink to be consumed, or granulated, encapsulated, and powdered to be consumed can do. In addition, it can be prepared in the form of a composition by mixing at least one of the strains of the present invention, their lysates and cultures with known substances or active ingredients known to have liver function improving effects. In addition, functional foods include beverages (including alcoholic beverages), fruits and their processed foods (e.g. canned fruit, bottled fruit, jam, marmalade, etc.), fish, meat and their processed foods (e.g. ham, sausage corned beef). etc.), breads and noodles (e.g. udon, buckwheat noodles, ramen, spaghetti, macaroni, etc.), fruit juice, various drinks, cookies, taffy, dairy products (e.g. butter, cheese, etc.), edible vegetable oil, margarine, vegetable protein , Retort food, frozen food, various seasonings (eg, soybean paste, soy sauce, sauce, etc.) can be prepared by adding at least one of the strain of the present invention, its lysate and culture group.

The preferred content of the strain of the present invention, its lysate and culture in the food composition of the present invention is not limited thereto, but is preferably 0.01 to 50% by weight of the final food product. In addition, the strain of the present invention, its lysate or its culture may be prepared and used in the form of a powder or concentrate in order to be used as an active ingredient in the form of a food additive.

In addition, the present invention is one or more strains selected from the group consisting of Lactobacillus pentosus KF8 (Accession No. KCCM11997P) strain, Bacillus subtilis KF11 (Accession No. KCCM11981P) strain and Lactococcus lactis KF140 (Accession No. KCCM11673P) strain, It is possible to provide a pharmaceutical composition for improving liver function comprising its lysate or its culture as an active ingredient.

The pharmaceutical composition may contain a pharmaceutically acceptable salt alone or may further contain one or more pharmaceutically acceptable carriers, excipients or diluents. A pharmaceutically acceptable carrier may further include, for example, a carrier for oral administration or a carrier for parenteral administration. Carriers for oral administration may include lactose, starch, cellulose derivatives, magnesium stearate, stearic acid and the like. In addition, the carrier for parenteral administration may include water, suitable oil, saline, aqueous glucose, glycol, and the like, and may further include a stabilizer and a preservative. Suitable stabilizers include antioxidants such as sodium bisulfite, sodium sulfite or ascorbic acid. Suitable preservatives include benzalkonium chloride, methyl- or propyl-paraben and chlorobutanol. As other pharmaceutically acceptable carriers, reference may be made to those described in the following literature (Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, PA, 1995).

The pharmaceutical composition of the present invention can be administered to mammals including humans by any method. For example, it can be administered orally or parenterally. Parenteral administration methods include, but are not limited to, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal, topical, sublingual or rectal administration can be Preferably, the pharmaceutical composition of the present invention can be administered orally or transdermally.

The pharmaceutical composition of the present invention may be formulated into a preparation for oral administration or parenteral administration according to the administration route as described above.

In the case of preparations for oral administration, the composition of the present invention may be formulated into powders, granules, tablets, pills, dragees, capsules, solutions, gels, syrups, slurries, suspensions, etc. using a method known in the art. can For example, preparations for oral use may be obtained by combining the active ingredient with a solid excipient, which is then milled and, after adding suitable auxiliaries, processed into a mixture of granules to obtain tablets or dragees. Examples of suitable excipients include sugars including lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol and maltitol, starches including corn starch, wheat starch, rice starch and potato starch, cellulose, Celluloses including methyl cellulose, sodium carboxymethylcellulose and hydroxypropylmethyl-cellulose, and the like, fillers such as gelatin, polyvinylpyrrolidone, and the like may be included. In addition, cross-linked polyvinylpyrrolidone, agar, alginic acid or sodium alginate may be added as a disintegrant, if desired. Furthermore, the pharmaceutical composition of the present invention may further include an anticoagulant, a lubricant, a wetting agent, a flavoring agent, an emulsifier, and a preservative.

In the case of preparations for parenteral administration, they may be formulated in the form of injections, creams, lotions, external ointments, oils, moisturizers, gels, aerosols, and nasal inhalants by methods known in the art. These formulations are described in Remington's Pharmaceutical Science, 15th Edition, 1975. Mack Publishing Company, Easton, Pennsylvania 18042, Chapter 87: Blaug, Seymour, which is a generally known formula for all pharmaceutical chemistry.

The total effective amount of the strain itself, its lysate, and the culture of the strain of the present invention can be administered to the patient in a single dose, and a fractionated treatment method in which long-term administration is performed in multiple doses. protocol). The pharmaceutical composition of the present invention may vary the content of the active ingredient according to the severity of the disease. Preferably, the preferred total dose of the strain of the present invention, its lysate and culture may be about 0.01 ug to 1,000 mg, most preferably 0.1 ug to 100 mg per kg of patient body weight per day. However, the dose of the strain itself, its lysate and the culture of the strain of the present invention depends not only on the route of administration of the pharmaceutical composition and the number of treatments, but also on the patient's age, weight, health condition, sex, severity of disease, diet and excretion rate, etc. Since the effective dosage for the patient is determined in consideration of various factors, considering this point, those with ordinary knowledge in the art can use the strain of the present invention, its lysate and culture according to specific uses as an immune function enhancer. Appropriate effective dosages will be determined. The pharmaceutical composition according to the present invention is not particularly limited in its formulation, administration route and administration method as long as it exhibits the effects of the present invention.

Further, in the present invention, improving liver function means treating, reducing, or preventing symptoms caused by liver damage, and refers to liver function, liver condition, liver disease, or treatment, reduction, or prevention of liver disease.

Liver diseases that can be caused by liver damage in the present invention are not limited thereto, but are not limited thereto, autoimmune liver disease, drug-induced liver disease, alcoholic liver disease, infectious liver disease, congenital metabolic liver disease, acute liver disease, hepatitis, biliary tract disease Stasis, fatty liver and chronic liver disease.

Hereinafter, the present invention will be described in more detail through examples. These examples are intended to explain the present invention in more detail, and the scope of the present invention is not limited to these examples.

<Preparation example>

<1> Preparation of test food containing the strain of the present invention

The inventors of the present invention requested three strains previously isolated and identified as new strains to a strain depository institution and received an accession number, and a total of three deposited strains (Lactobacillus pentosus KF8, Bacillus subtilis KF11, Lactococco Lactococcus lactis KF140) was commissioned by Mediogen Co., Ltd. to prepare a test food.

A total of three strains used in the present invention are as follows.

-Lactobacillus pentosus KF8: A strain deposited with the Korea Center for Microorganisms (KCCM), an international microorganism depository, on March 24, 2017 and given accession number KCCM 11997P was used.

-Bacillus subtilis KF11: The strain deposited with the Korea Microorganism Conservation Center (KCCM), an international microorganism depository, on February 24, 2017, and given the accession number KCCM 11981P was used.

-Lactococcus lactis KF140: The strain deposited at the Korea Center for Microorganism Conservation (KCCM), an international microorganism depository, and given the accession number KCCM 11673P was used.

The production of test foods using these strains was commissioned by Mediogen Co., Ltd. and manufactured according to the conventional method for producing strain-type products. ⁹ CFU/g), packaged in units of 1.5 g per pack, and stored in a refrigerator until not used for testing.

At this time, each of the strains used for the production of the test food was cultured in a culture medium to obtain a strain, and then a strain in the form of a powder obtained by freeze-drying and powdering was used.

A photograph of the test food prepared for use in the present invention is shown in FIG.

<2> Test subjects

The following test subjects were selected in order to confirm the effect of improving liver function on the three strains of the present invention.

Subjects were selected as those who met the following criteria, and only those who passed the selection criteria by volunteering for human body application test subjects were selected for the following experiments. For the subjects, a total of 44 adults between the ages of 25 and 45 residing in the Daegu-Gyeongbuk region were selected, and 36 people who met the selection criteria and did not meet the exclusion criteria were selected as subjects.

Subject selection criteria were limited to those who could be followed up during the test period and those who voluntarily signed the consent form after receiving sufficient explanations about the purpose and content of the study.

Meanwhile, those who fall under the following conditions are excluded.

- Those who have experienced hypersensitivity reactions when ingesting strain products

- A person who has taken prescription drugs, over-the-counter drugs, health functional foods, or probiotics products within the past month

- Those who have taken antibiotics within 1 month of participating in the test

- Those who have undergone gastroenterological or colonoscopy within 1 month of participating in the test

- Those with a BMI of less than 20 or greater than 35

- Those with hypertension (systolic blood pressure 160 mmHg or diastolic blood pressure 100 mmHg or more)

- A person with a fasting blood glucose concentration of over 110

- A person whose ALT or AST exceeds twice the upper limit of normal

- Pregnant or lactating women

- Women of childbearing age who do not consent to contraception using medically proven methods (e.g. condoms, loops, femidoms, etc.) during the trial period

- Those who need continuous treatment due to anorexia, depression, bipolar disorder, psychiatric disease, etc.

- Those with systemic diseases such as immune-related diseases, severe liver or kidney failure, malignant tumors, lung diseases, collagenosis, multiple sclerosis, allergic skin diseases and other autoimmune diseases

- Those with a history of gastrointestinal disease or gastrointestinal surgery (excluding simple appendectomy or hernia surgery) that may affect the absorption of the test food

- A person who participated in another human application test or clinical trial within 3 months of participating in the test and consumed the test product (except for cosmetics human application test)

- In addition to the above, those who are judged to be difficult to perform the test at the discretion of the researcher

In addition, on the day of hospitalization, the following subjects were excluded from this study.

- A person who consumed alcohol in excess of 50g (more than 1 bottle of soju or more than 2 bottles of beer) per drink within 2 weeks before hospitalization

- A person who drank more than 1 glass of soju or 1 glass of beer per day within 1 week before hospitalization

- Those who consumed dairy products, fast food such as hamburgers and pizza, instant food, fried foods, and grilled foods within 1 week before hospitalization

- Those who have taken antibiotics since the previous visit date

- Those who have undergone gastrointestinal or colonoscopy after the previous visit

- Those who have taken prescription drugs, over-the-counter drugs or health functional foods since the previous visit date

The subjects selected under these conditions were set to be 10 subjects per experimental group as the minimum number of subjects for efficacy analysis.

The clinical trial of the selected subjects was conducted according to the regulations of the Institutional Review Board (IRB).

<Example 1>

Analysis of liver function improvement effect according to ingestion of strain of the present invention

Changes in AST, ALT, total cholesterol, triglyceride, LDL cholesterol, and HDL cholesterol in the blood were measured using blood collected before and after ingestion of each strain for 26 days for the test subjects.

As a result of the analysis, as shown in Table 1 above, in the group ingesting the strains of the present invention, Lactobacillus pentosus KF8, Bacillus subtilis KF11 and Lactococcus lactis KF140, respectively, liver function index ALT ( It was found that the levels of Alanine Aminotransferase) and Aspartate Aminotransferase (AST) were more effectively inhibited than before ingesting the strain.

Therefore, through these results, the present inventors can see that the strains of Lactobacillus pentosus KF8, Bacillus subtilis KF11 and Lactococcus lactis KF140 can be used for the purpose of improving liver function and preventing and treating liver disease. there was.

<Example 2>

Analysis of liver function improvement effect according to ingestion of strain of the present invention in liver damage-induced animal model

Male SD (Sprague-Dawley) rats (SLC, Japan) weighing 200 g were used as experimental animals, and 5 horses were distributed to each experimental group and used in the experiment. Each experimental group is as follows.

administration content Normal group normal dietary intake control group Normal diet + intraperitoneal administration of carbon tetrachloride Experiment group 1 Normal diet + intraperitoneal administration of carbon tetrachloride + administration of Lactobacillus pentosus KF8 experimental group 2 Normal diet + intraperitoneal administration of carbon tetrachloride + administration of Bacillus subtilis KF11 Experiment group 3 Normal diet + intraperitoneal administration of carbon tetrachloride + administration of Lactococcus lactis KF140

At this time, the carbon tetrachloride was administered as a 50% solution mixed with corn oil intraperitoneally to rats at a dose of 0.75 ml / kg twice a week for 4 weeks, and the experimental groups were prepared in the preparation example. Functional powder containing the strain of the present invention 50 mg/kg of each food was suspended in a 1% CMC solution and orally administered once a day, 6 times a week. Then, after the administration was continued for 4 weeks, the animals were sacrificed to obtain serum, and in order to examine the therapeutic effect of the strain of the present invention on liver damage induced by carbon tetrachloride, ALT and AST activities were measured.

ALT and AST concentration measurement results ALT(U/T) AST(U/T) Normal group 70±10 85±22 control group 182±12 200±42 Experimental group 1 (KF8) 92±21 100±13 Experimental group 2 (KF11) 87±17 98±21 Experimental group 3 (KF140) 89±22 96±35

As a result of the analysis, as shown in Table 3, in the case of the mouse group ingested the strain of the present invention, it was found that ALT and AST elevated in serum due to carbon tetrachloride were effectively suppressed.

These results indicate that the Lactobacillus pentosus KF8, Bacillus subtilis KF11 and Lactococcus lactis KF140 strains of the present invention have excellent hepatoprotective and liver function effects against hepatotoxicity.

<Example 3>

Analysis of improvement effect according to ingestion of strain of the present invention in fatty liver animal model

Male C57BL/6 mice (Central, Korea) weighing 20 g were used as experimental animals, and 9 mice were distributed to each experimental group and used in the experiment. Each experimental group is as follows. A high-fat diet (40% fat) was provided in the form of pellets as a substance for inducing fatty liver, and the CML reactant was orally administered daily at a dose of 10 mg/kg. Then, after administering the strain of the present invention to each mouse, the degree of fatty liver improvement was analyzed.

administration content Normal group normal dietary intake control group High-fat diet + CML diet Experiment group 1 High-fat diet + CML diet + Lactobacillus pentosus KF8 administration experimental group 2 High-fat diet + CML diet + Bacillus subtilis KF11 administration Experiment group 3 High-fat diet + CML diet + Lactococcus lactis KF140 administration

At this time, the experimental groups suspended 1×10 ⁷ CFU of the strain of the present invention in a 0.9% saline solution and orally administered once a day, 6 times a week. Then, after the administration was continued for 4 weeks, the animals were sacrificed, and the blood was taken to measure the contents of enzymes related to liver function and triglyceride.

Liver function-related enzymes and triglyceride concentration measurement results AST (U/L) ALT (U/L) Triglycerides (mg/g) Normal group 44.5±1.7 19.7±1.1 62.3±7.2 control group 64.2±1.2 31.2±2.0 85.5±7.2 Experimental group 1 (KF8) 48.4±2.6 24.4±2.8 68.4±5.0 Experimental group 2 (KF11) 48.6±3.4 27.5±1.6 66.3±7.4 Experimental group 3 (KF140) 43.1±2.5 24.3±1.7 59.5±6.8

As a result of the analysis, as shown in Table 7, in the case of the mouse group ingesting the strain of the present invention, the levels of AST and ALT, which increase due to liver damage, were significantly suppressed, and additionally, the content of neutral fat also increased. The preventive effect was confirmed.

Through these results, the present inventors found that the Lactobacillus pentosus KF8, Bacillus subtilis KF11 or Lactococcus lactis KF140 strain of the present invention prevents liver damage caused by glucose toxin intake to improve and treat liver diseases such as fatty liver. found to be effective.

So far, the present invention has been looked at with respect to its preferred embodiments. Those of ordinary skill in the art to which the present invention pertains will understand that the present invention can be implemented in a modified form without departing from the essential characteristics of the present invention. Therefore, the disclosed embodiments should be considered from an illustrative rather than a limiting point of view. The scope of the present invention is shown in the claims rather than the foregoing description, and all differences within the equivalent scope will be construed as being included in the present invention.

Korea Microbial Conservation Center (Overseas) KCCM11997P 20170324 Korea Microbial Conservation Center (Overseas) KCCM11981P 20170224 Korea Microbial Conservation Center (Overseas) KCCM11673P 20150306

Claims (5)

A health food composition for improving liver function, comprising Lactococcus lactis KF140 (accession number KCCM11673P) strain, a lysate thereof or a culture thereof as an active ingredient.
According to claim 1,
The composition is
Inhibits ALT (Alanine Aminotransferase) or AST (Aspartate Aminotransferase) activity,
Inhibits the increase in the concentration of total cholesterol or triglycerides in the liver, or
Characterized by inhibiting fat accumulation in the liver,
Health food composition for improving liver function. According to claim 1,
The health food composition is a health food composition for improving liver function, characterized in that any one formulation selected from powder, granule, pill, tablet, capsule, candy, syrup and beverage. Lactococcus lactis KF140 (accession number KCCM11673P) strain, a pharmaceutical composition for improving liver function, comprising a lysate thereof or a culture thereof as an active ingredient.

According to claim 4,
The composition is
Inhibits ALT (Alanine Aminotransferase) or AST (Aspartate Aminotransferase) activity,
Inhibits the increase in the concentration of total cholesterol or triglycerides in the liver, or
Characterized by inhibiting fat accumulation in the liver,
A pharmaceutical composition for improving liver function.